Tuesday, November 19, 2013

Tuesday 111913

Okay, what this guy does is probably not much different than what a well trained gymnast does but it is pretty impressive what he does with a pull up bar.  Still what Claude does will get way more attention.  Understandable.

Then there is the positive mindset of this guy.

Slice the Hokas in half and this is what you have.

AM – I have full week of meetings this week (sort of like business travel but I am here in CO instead), so I got out early.  5.2 miles easy in the cool before the dawn.  Work might help me stick a lower mileage approach than my choosing to do that explicitly.  At least this week.

As dorky as it sounds, this 2 hour and 25 minute testimony to a subcommittee of Congress will be the next thing I watch (or listen to on my next run).

8 comments:

  1. Hi GZ,

    Thanks for the link to the 'dorky' subcommittee meeting on 'software as medical device'. Having been on the technical side in that industry for the later half of my career, I found the testimony very interesting- and a bit scary given some of what transpired. I must say that the long-term hazards of getting legislation (and legislators) involved in the process may outweigh the initial guidance that a law may provide. Having to revisit the law as the technology evolves seems byzantine, at least from my experience. It seems a bit naive to think that establishing general guideline areas at this juncture will have validity even in 2 years. The rationalization today may very well impede innovation and business planning in the near future. Potential dependence upon the glacial movement of our legislators would be a very large risk factor that one must include in any long term business plan. I would be more inclined to work with the FDA on a continuing basis and exert 'pressure' when need be via the typical channels rather than be exposed to the vagaries of an unknown political environment.

    I should hope that the FDA realizes how important this area is and that they place a good measure of focus on it to develop a flexible framework that both encourages innovation, protects the patient, and provides sufficient bandwidth to respond to submissions (something that they have not been very good at in the past). As you likely know the interactions between software and therapy/diagnostic devices and/or patient records is complex. The delineation as to exactly where a line can be drawn w/r/t patient safety becomes muddled in the clinical setting particularly given the rate of change on all fronts.

    I was surprised at how many times the various participants used the term 'space'.... I guess they think it makes them sound more informed/knowledgeable/sophisticated?

    ReplyDelete
    Replies
    1. Okay. Wow. Someone actually interested in regulatory stuff. That I don't work with. Or maybe I do and I don't know that.

      I am only about half way through the vid.

      I generally agree with what Shuren is proposing - don't pass the software act. I think the FDA is very aware they are being carefully watched for "over reaching." Even without the software act to seatbelt them away from various healthcare software, they will be called to task pretty quickly if they push on some developer of an app without just cause.

      I have not heard the comments in the vid yet from industry but I think I am gathering they will be supportive of the legislation. Really this is a law to keep the FDA out of their hair - and a step to I think further assure that the ONC will stay out of the way as well. If that is the way they pitch it, I see a bit of irony there: the very groups that typically are not interested in laws being passed because they could stifle innovation are lobbying to have a law passed to keep a government entity at bay, so they can supposedly innovate.

      The guidance approach they currently have is probably the best approach. I can't see the law passing given how murky it is, the fresh ink of the guidance (just published in Sept), the to be published guidance (Jan/Feb). The FDA will be watched carefully not to overreach, but if their is an event that is adverse, it leaves the door open for the FDA to jump in.

      And yeah, listening to Congress is generally hilarious. Another recent example of this I heard is where I was listening to politicians talk about software development cycles with the healthcare.gov fiasco. Made me realize how little they knew what occurred in that space. Perhaps as clueless is some of the reporting media types, and that is really scary

      Delete
    2. Fair recap: http://www.mddionline.com/article/software-not-medical-device-house-holds-hearing-software-act

      Delete
    3. Yes, the reporter does a good job of summarizing. I do not often align with Waxman but his concerns seem well founded.

      The guy from McKesson expressed a significant position in favor of the legislation. I think they (McKesson) will be well served to think about this a bit more and let the landscape develop before they work to lock in some currently favorable legislation. Too many things change, too fast, and in some unexpected ways. Best to keep as much flexibility as possible for the future. But I will assume they know what they are doing and have some strategy that is perhaps not obvious because they know about bunch of important 'background' particulars that are not public (yet).

      Agreed on the laughable response of the house and senate to what happened with healthcare.bomb...

      in this case the 'vivid imagination' of one house member 'dreaming' of a future of remote diagnosis, therapy, and care, such as for heart disease- well it already exits and has for over 10 years (e.g. Medtronic CareLink (now called ConnectedCare).

      thanks again for putting up the link- been away from that stuff for a while, don't miss it but it is still interesting.

      Delete
    4. Robert - do I know you? HIT is a pretty small world.


      Delete
  2. Hi GZ,

    Not likely... I am too old and only lived on the periphery of the HIT sphere. I spent the second half of my career as a scientist and internal technology consultant at a large international medical company that acquired many many companies during my tenure. In addition to running a small R&D group and developing strategic technical business strategies (aka company-wide 'visioning'), I played a role in technical due diligence in acquisitions. This exposed me to a lot of stuff that I had to come up to speed on very quickly. Fortunately a background in physics, mathematics, and computer science served as a reasonable basis. In was in this activity area that I spent some time understanding and doing a bit of work in HIT.

    ReplyDelete
    Replies
    1. Well damn, that only piques my interest about you all the more (particularly in light of your other already other interesting comments on the blog). I hope we can share a few strides sometime.

      Delete
  3. Hi GZ,

    Absolutely... have not been to Boulder since the 1983 Coors Classic.... my wife tells me things have changed....

    If I do make it there I will send an email and perhaps we can give Green a go.

    ReplyDelete